Filing Flows › Kiniksa Pharmaceuticals International (KNSA) › Q3 2026
Kiniksa Pharmaceuticals International (KNSA) Q3 2026 earnings results (third quarter 2026)
10-Q filed Oct 27, 2026
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $286M for the third quarter 2026 (Q3 2026), +58% from a year earlier and +17% from the quarter before. Operating margin was 19.0%, net earnings $47.3M (16.6% of revenue).
Kiniksa Pharmaceuticals International, Q3 2026: revenue $286M (+58% year over year), operating margin 19.0%, net earnings $47.3M, operating cash flow $47.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $286M | +17% | +58% |
| Operating profit | $54.2M | +99% | +126% |
| Net earnings | $47.3M | +86% | +157% |
| Operating cash flow | $47.5M | +0.7% | +41% |
| Free cash flow | $47.4M | +2% | +44% |
What changed
Revenue was $286.0M in Q3 2026, up 58% year over year and up 17% from the previous quarter.
Operating profit was $54.2M, a 19.0% margin (up 5.7 points year over year). Of the extra revenue versus Q3 2025, 29% reached operating profit, above the 13% margin then. Total costs grew 48% against revenue growth of 58%. The fastest-growing cost line was Other operating costs (+67%). Net earnings were $47.3M, up 157% year over year. The effective tax rate was 19.8%.
Operating cash flow was $47.5M (up 41% year over year), 100% of net earnings. Non-cash charges added back $490K of depreciation and amortization and $13.1M of share-based compensation. Working capital and other items used $13.4M. Capital expenditures of $180K left free cash flow of $47.4M.
Questions
What was Kiniksa Pharmaceuticals International's revenue in the third quarter 2026?
Kiniksa Pharmaceuticals International (KNSA) reported revenue of $286M for the third quarter 2026 (Q3 2026), +58% from a year earlier and +17% from the quarter before.
Was Kiniksa Pharmaceuticals International profitable in the third quarter 2026?
Operating profit was $54.2M (19.0% of revenue) and net earnings $47.3M.
Source: Kiniksa Pharmaceuticals International 10-Q on SEC EDGAR.